VJHemOnc is committed to improving our service to you

IMW 2019 | Identifying surrogate markers for survival in MM

VJHemOnc is committed to improving our service to you

David Siegel

David Siegel, MD, PhD, John Theurer Cancer Center, Hackensack, NJ, discusses the evergrowing need to identify novel surrogate markers for survival, including MRD and other endpoints, such as time to MRD negativity relapse, among others presented at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter